The Real Endpoints team is taking on PCMA today and tomorrow in Orlando. Would love to touch base if you are attending!
read full article ›At Real Endpoints, Rare Disease Day isn't just another awareness day—it's personal. Many of us here have been directly touched by the challenges and triumphs associated with living with a rare disease, whether through personal experience or those of friends and loved ones.
read full article ›The team at Real Endpoints has been working tirelessly to improve RE Assist, a simple, easy-to-use AI-based platform designed to solve a critical gap in the market: providing patients with real-time information about available third-party foundation dollars for prescription meds.
read full article ›As Interest Rates Begin to Drop, which Biotechs Will Get an Unfair Share of New Investment?
read full article ›Your semi-regular reminder: Healthcare. Is. Hard.
read full article ›This new Health Affairs Forefront article explains in simple language why it's past time to update the methodology underpinning how we value - and ultimately price - drugs.
read full article ›But for me the big point is: CMS has done something bold and novel – creating what could be a path to getting life-altering but extremely expensive therapies to people who simply wouldn’t be able to get them otherwise. Yes, the unknowns loom large. The biggest: will the counterparties – Medicaid plans and manufacturers – want to play?
read full article ›Thoughts from Roger Longman on Arena Bioworks and new models for creating differentiated innovations for patients and the healthcare system. TLDR: An interesting BUT expensive experiment.
read full article ›Coming out of the overwhelming focus on obesity drugs during the JPMorgan Chase & Co. Healthcare Conference, Eli Lilly and Company and Novo Nordisk have both taken beginning of the year price increases.
read full article ›There was much discussion at hashtag#JPM2024 on the travails of cell therapy companies. Real Endpoints co-founder Roger Longman has been thinking about the challenges and opportunities.
read full article ›